Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yihua Gu

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Molecular & Cellular Proteomics : MCP|July 2, 2016
A Human Lectin Microarray for Sperm Surface Glycosylation AnalysisYangyang Sun, Li Cheng, Yihua Gu, et al.
American Journal of Translational Research|July 18, 2019
Multiple facilitated glucose transporters SLC2As are required for normal mouse preimplantation embryo developmentSamuel Kofi Arhin, Junzhao Zhao, Xu Ji, et al.
The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|September 18, 2017
Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativaIltefat H Hamzavi, Murali Sundaram, Cynthia Nicholson, et al.
Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.
Journal of the American Academy of Dermatology|June 4, 2018
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension studyChristos C Zouboulis, Martin M Okun, Errol P Prens, et al.
Lancet (London, England)|July 9, 2019
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trialKristian Reich, Melinda Gooderham, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trialBoni E Elewski, Martin M Okun, Kim Papp, et al.
Development (Cambridge, England)|May 20, 2021
Regulation of the mammalian maternal-to-embryonic transition by eukaryotic translation initiation factor 4EYan Li, Jianan Tang, Xu Ji, et al.
Journal of Neuroscience Research|July 16, 2008
Topology and patch-clamp analysis of the sodium channel in relationship to the anti-lipid a antibody in campylobacteriosisSeigo Usuki, Yoshihiko Nakatani, Kyoji Taguchi, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Molecular & Cellular Proteomics : MCP|July 2, 2016
A Human Lectin Microarray for Sperm Surface Glycosylation AnalysisYangyang Sun, Li Cheng, Yihua Gu, et al.
American Journal of Translational Research|July 18, 2019
Multiple facilitated glucose transporters SLC2As are required for normal mouse preimplantation embryo developmentSamuel Kofi Arhin, Junzhao Zhao, Xu Ji, et al.
The Journal of Investigative Dermatology|October 21, 2011
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasisKenneth B Gordon, Richard G Langley, Alice B Gottlieb, et al.
Journal of the American Academy of Dermatology|September 18, 2017
Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativaIltefat H Hamzavi, Murali Sundaram, Cynthia Nicholson, et al.
Journal of the American Academy of Dermatology|October 16, 2007
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialAlan Menter, Stephen K Tyring, Kenneth Gordon, et al.
Journal of the American Academy of Dermatology|June 4, 2018
Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension studyChristos C Zouboulis, Martin M Okun, Errol P Prens, et al.
Lancet (London, England)|July 9, 2019
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trialKristian Reich, Melinda Gooderham, Diamant Thaçi, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trialBoni E Elewski, Martin M Okun, Kim Papp, et al.
Development (Cambridge, England)|May 20, 2021
Regulation of the mammalian maternal-to-embryonic transition by eukaryotic translation initiation factor 4EYan Li, Jianan Tang, Xu Ji, et al.
Journal of Neuroscience Research|July 16, 2008
Topology and patch-clamp analysis of the sodium channel in relationship to the anti-lipid a antibody in campylobacteriosisSeigo Usuki, Yoshihiko Nakatani, Kyoji Taguchi, et al.
Pageof 6